THE IMPORTANCE OF GOOD ADHERENCE TO METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS

  • Jelena Ceranic VMA, Klinika za reumatologiju
  • Darija Kisic Tepavcevic
  • Gorica Ristic
DOI: https://doi.org/10.5937/mp76-46065
Keywords: rheumatoid arthritis, adherence, methotrexate, treatment

Abstract


Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by symmetrical peripheral polyarthritis and progressive joint damage. Disease-modifying antirheumatic drugs (DMARDs) reduce disease activity, and radiological progression of the joints, and improve the long-term functional status of patients with RA. The precondition for these positive outcomes is adequate patient adherence to DMARDs. According to the latest EULAR (The European Alliance of Associations for Rheumatology) recommendations, methotrexate (MTX) is still the first-line drug for the treatment of RA. It is characterized by safety and effectiveness, different ways of administration, the possibility of dose titration, as well as low treatment costs. It can be used as monotherapy or in combination with other synthetic or biological DMARDs. Methotrexate is an antimetabolite, a structural analog of folic acid, which inhibits the de novo synthesis of purines and pyrimidines, necessary for the synthesis of DNA and RNA, but acts on inflammation and other mechanisms such as increased release of adenosine, inhibition of the transmethylation reaction, reduced accumulation of polyamines and separation of nitric oxide synthase. Methotrexate affects the function of almost all cell types involved in inflammation (neutrophils, monocytes, T and B cells, endothelial cells, and fibroblast-like synovium). However, not all patients respond well to MTX, which can partly be explained by non-adherence. Optimal use of MTX involves starting therapy without delay, following the recommended dose and regimen until a satisfactory response to therapy is achieved, and following the maintenance dose. More than 200 variables influencing adherence have been identified, but none of these variables have been consistently linked in all previous research. Therefore, it is not possible to create a specific risk profile for non-adherence. Considering this fact and the existence of a significant number of non-adherent patients, there is a need to find tailored interventions to improve adherence to MTX in patients with RA that could improve the final outcomes of the disease.

 

References


  1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.

  2. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-22

  3. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551-1557.

  4. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken). 2013;65(6):870-8.

  5. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-9.

  6. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.

  7. Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol. 2013;25(6):728-35.

  8. Muller S, Radic M. Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms. Clin Rev Allergy Immunol. 2015;49(2):232-9.

  9. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.

  10. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233-55.

  11. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62:ii60-7.

  12. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656-64.

  13. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32(1):1-7

  14. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11(3):234-50.

  15. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010; 49:15-24.

  16. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243-52.

  17. Zhang Z, Bridges SL Jr. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am. 2001;27(2):335-53.

  18. Martinez-Gamboa L, Brezinschekb H-P et al. Immunopathological role of B lymphocytes in rheumatoid arthritis: Rationale of B cell directed therapy. Autoimmunity Reviews. 2006;5:437-42

  19. Emery P. Suarez-Almazor M. Rheumatoid arthritis. Clin. Evid 2003;1454-76.

  20. Turesson, C. and Matteson, E.L. Is atherosclerosis in rheumatoid arthritis related to disease severity and extraarticular manifestations? Arthritis & Rheumatism, 2006; 54: 1353-1353.

  21. Panichi V, Migliori M, De Pietro S et al. The link of biocompatibility to cytokine production. Kidney Int 2000; 58:96-103.

  22. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63

  23. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24: 469-80.

  24. de Benedetti F, Rucci N, Del Fattore A et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54: 3551-63

  25. Hewlett S, Cockshott Z, Byron M et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.

  26. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004;51: 578-85.

  27. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-91.

  28. Theander L, Nyhäll-Wåhlin BM, Nilsson JÅ, Willim M, Jacobsson LTH, Petersson IF, Turesson C. Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. J Rheumatol. 2017;44(7):981-987.

  29. Weinblatt ME. Methotrexate: who would have predicted its importance in rheumatoid arthritis? Arthritis Res Ther. 2018;20(1):103.

  30. Schiff MH, Sadowski P. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis. Rheumatol Int. 2017;37(2):213-218.

  31. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907-12.

  32. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAnnals of the Rheumatic Diseases 2023;82:3-18.

  33. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74(1):27-34.

  34. de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73(7):1331-9.

  35. Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75-85.

  36. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al; CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arthritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis. 2008; 67: 656-663.

  37. Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M. Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis. 2006; 65: 1449-1455.

  38. Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M. Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatol Int 2017; 37:897–904.

  39. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68:1–26.

  40. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 2017; 9:67–79.

  41. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open. 2016; 2: e000171.

  42. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003;30(11):2469–2475

  43. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011.

  44. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997;32:345–56.

  45. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016; 35: 1335-1339.

  46. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44-54.

  47. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012; 8: 337-351.

  48. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open. 2016;2(1):e000171.

  49. Harnett J, Wiederkehr D, Gerber R, Gruben D, Bourret J, KoenigA. Primary nonadherence, associated clinical outcomes and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease‐modifying antirheumatic drugs. J Manag Care and Spec Pharm 2016;22: 209–18.

  50. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing methotrexate adherence in rheumatoid arthritis: a cross‐sectional survey. Rheumatol Ther 2015;2:73–84

  51. Contreras-Yáñez I, Ponce De León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010 Oct;340(4):282-90

  52. Hanlon P, Nicholl BI, Jani BD, McQueenie R, Lee D, Gallacher KI, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open. 2018;8(1):e018404.

  53. Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nat Rev Rheumatol 2016;12:532–42.

  54. Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012;10:66.

  55. Moss-Morris R, Weinman J, Petrie KJ et al. The revised illness perception questionnaire (IPQ-R). Psychol Health 2002;17:1–16.

  56. Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M, Beauvais C, et al. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine. 2019;86(1):13-19.

  57. Yajima N, Kawaguchi T, Takahashi R, Nishiwaki H, Toyoshima Y, Oh K, et al. Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study. BMC Rheumatol. 2022;6(1):75.


 


 

Published
2025/05/09
Issue
Vol. 76 No. 1 (2025): Medicinski podmladak
Section
Mini pregledni članak